Related by context. All words. (Click for frequent words.) 78 FDA Approvable Letter 73 FDA Complete Response 71 Marketing Authorisation Application 71 Approvable Letter 71 FDA approvable letter 70 Complete Response letter 70 Marketing Authorization Application 69 PDUFA Date 69 Biological License Application 69 Marketing Authorisation Application MAA 68 Complete Response Letter 68 Biologics License Application BLA 68 Premarket Approval Application 68 Biologic License Application 68 T Pred 68 Resubmission 68 Biologics License Application 68 NDA Submission 68 balsalazide tablet 67 Orathecin 67 Approvable 67 Pivotal Phase III 67 Supplemental Biologics License Application 67 FDA Accepts 67 Intermezzo ® NDA 67 Files Investigational 67 Fast Track Status 66 Accelerated Approval 66 alvimopan 66 MAA submission 66 BLA filing 66 supplemental Biologics License Application 66 sBLA 66 Phase 2a Trial 66 Expedited Review 66 Clinical Trial Data 65 Telavancin 65 Cellegesic 65 Biologic License Application BLA 65 Tezampanel 65 BLA submission 65 PROMACTA 65 sNDA 65 HoFH 65 Phase 2b Clinical Trial 65 Submits NDA 65 balsalazide 65 IND Application 64 Marketing Authorization Application MAA 64 Efficacy Results 64 ARCOXIA 64 IND Filing 64 Investigational Compound 64 Patient Enrollment 64 Expanded Indication 64 Saforis 64 Cimzia TM 64 Act PDUFA date 64 Product Monograph 64 New Drug Application 64 MAGE A3 ASCI 64 Alogliptin 64 lorcaserin NDA 64 Premarket Approval PMA 64 Phase III Clinical Trial 64 Pivotal Clinical Trial 64 oral ridaforolimus 64 Priority Review 64 Dyloject TM 64 NDA resubmission 63 JAK Inhibitor 63 PMA Supplement 63 Granted Orphan Drug 63 L MTP PE 63 Phase IIb Clinical Trial 63 Audited Financials 63 Premarket Approval 63 Cethromycin 63 ZEGERID Chewable Tablets 63 Not Approvable 63 ORENCIA ® 63 Extina 63 UPLYSO 63 ZOLINZA 63 CIP TRAMADOL ER 63 ENTEREG ® 63 Ranolazine 63 Oral Calcitonin 63 XYOTAX TM 63 ULTRASE 63 PROVENGE sipuleucel T 63 Onrigin 63 Novel Antibiotic 62 FOLOTYN ® 62 IL# PE#QQR 62 nonclinical studies 62 HDAC Inhibitor 62 QNEXA 62 Brentuximab Vedotin SGN 62 Drug Submission 62 Sanctura XR 62 Ereska 62 severe hypercholesterolemia 62 ADVEXIN 62 refractory chronic lymphocytic 62 PMA submission 62 INC# 62 inspectional observations 62 NEBIDO 62 dextromethorphan quinidine 62 BRILINTA 62 Hedgehog Pathway Inhibitor 62 Metastatic Melanoma 62 Pivotal Phase 62 Neurodex 62 MERLIN TIMI 62 Clinical Trial Results 62 Cinacalcet HCl 62 ONGLYZA ™ 62 Investigational Treatment 62 Survival Benefit 62 Velcade bortezomib 62 Orphan Status 62 Xenazine ® 62 cinacalcet HCl 62 GSK# [001] 62 Investigational Agent 62 Meets Primary Endpoint 62 PLK1 SNALP 62 Zarnestra 62 Ambrisentan 62 Citizen Petition 62 Junovan 62 Dacogen injection 62 LibiGel ® 62 Pralatrexate 62 Phase 2b Trial 62 PREOS 62 Phase III Clinical Trials 62 Fibrillex TM 62 tafamidis 62 SILENOR 62 Prolongs Survival 62 Milestone Payment From 62 peginesatide 62 Diabetic Nephropathy 62 Romiplostim 62 Civacir 62 prucalopride 61 Phase IIb Trial 61 Milestone Payments 61 OPAXIO 61 Febuxostat 61 Advexin 61 Targretin capsules 61 eltrombopag 61 Orphan Drug Status 61 MEND CABG II 61 TYKERB 61 FDA Clearance 61 Completes Patient Enrollment 61 Phenoptin 61 PRECISE trial 61 methylnaltrexone 61 Fast Track designations 61 octreotide implant 61 Orapred ODT 61 Levoleucovorin 61 GRAS Status 61 Submits Investigational 61 ruxolitinib 61 Panzem R 61 teduglutide 61 Anturol TM 61 Zenvia Phase III 61 Dupuytren Contracture 61 Pafuramidine 61 Approvable letter 61 Marketing Authorisation 61 FDA Oncologic Drugs 61 Phase 2a Clinical Trial 61 LibiGel NDA 61 ORENCIA R 61 GATTEX TM 61 ZEGERID Capsules 61 Alvesco R 61 Dalbavancin 61 CINTREDEKIN BESUDOTOX 61 elotuzumab 61 Triapine R 61 Azedra 61 Pegloticase 61 STELARA TM 61 TORISEL 61 Phase 1b Clinical Trial 61 NEO3 61 NDA submission 61 Fast Track Designation 61 HP Acthar Gel repository 61 Muraglitazar 61 FDA Orphan Drug 61 See CLINICAL PHARMACOLOGY 61 Paragraph IV Notice 61 rALLy trial 61 Velac 61 Bezielle 61 NASDAQ Listing Qualification 61 Dose Ranging Study 61 ixabepilone 61 brivaracetam 61 Milestone Payment 61 Pivotal Trial 61 MyVax R 61 TYGACIL 61 oral methylnaltrexone 61 Advanced Melanoma 61 Marketing Authorization Applications 61 SPRYCEL ® 61 pseudobulbar affect PBA 61 interferon gamma 1b 61 Vion Pharmaceuticals 61 Vernakalant 61 DORIBAX 61 RSR# 61 Demonstrates Significant 60 indiplon capsules 60 paliperidone ER 60 lucinactant 60 Glufosfamide 60 Combidex 60 Sapacitabine 60 Positive Opinion 60 Emezine 60 Icatibant 60 R lenalidomide 60 rasagiline tablets 60 BioDelivery Sciences 60 EOquin 60 approvability 60 Testosterone Gel 60 FDA Approvals 60 APF# NDA 60 VALSTAR 60 Inhaled Insulin 60 Oncologic Drugs Advisory 60 octreotide acetate 60 Mycophenolate Mofetil 60 Cutaneous T 60 ARIKACE 60 Cholesterol Lowering Drug 60 Octreolin 60 Phase III Pivotal 60 Calcium Acetate 60 mifamurtide 60 Phase 2b Study 60 Golimumab 60 dalbavancin 60 IND submission 60 BRIM2 60 ALN HPN 60 Initiate Clinical Trial 60 k Premarket Notification 60 Pre IND 60 Metformin HCl 60 RAPAFLO 60 oxymorphone ER 60 Pirfenidone 60 Catena ® 60 Increlex R 60 Anti Tumor Activity 60 Receives Fast Track 60 PrevOnco 60 Marketing Authorization 60 Generic Version 60 Bazedoxifene 60 CIMZIA ™ 60 Mylan Receives Approval 60 Aflibercept 60 ANTEGREN 60 Ticagrelor 60 corticotropin injection 60 vismodegib 60 Soriatane 60 BLP# Liposome Vaccine 60 Glatiramer Acetate 60 plasma kallikrein inhibitor 60 Phase III Trial 60 RIGScan CR 60 Single Dose 60 efalizumab 60 Sensipar 60 Omigard 60 Submits Response 60 GRAS notification 60 investigational humanized monoclonal antibody 60 Initiates Phase III 60 Luveniq 60 anidulafungin 60 CRMD# 60 Complete Response Letter CRL 60 Xinlay 60 Preclinical Data 60 Eltrombopag 60 FDA Advisory Panel 60 Pruvel 60 BYDUREON 60 Entereg R 60 PIX# [002] 60 ® decitabine 60 PANVAC VF 60 DOR BioPharma Announces 60 Silenor NDA 60 ISTODAX 60 Psoriasis Drug 60 PEG SN# 60 Zenvia ™ 60 Receives Approvable Letter 60 Dacogen decitabine 60 OMP designation 60 severe gastroparesis 60 Adjuvant Treatment 60 Zenvia 60 vernakalant hydrochloride 60 sNDA submission 60 Nabi HB Intravenous 60 Ramelteon 60 BEMA TM LA 60 Archexin 60 Prestara 60 Vandetanib 60 liver resection surgeries 60 Biologics Licensing 60 TRISENOX ® 60 NOXAFIL 60 Ustekinumab 60 Anti Infective Drugs 60 Paragraph IV 60 Sunesis Pharma 60 Adverse Event 60 Raptiva R 60 Sprycel dasatinib 60 Warning Letter 60 novel histone deacetylase 60 Surfaxin lucinactant 60 Hepatotoxicity 59 Receives Complete Response 59 Actemra tocilizumab 59 PREOS R 59 Orphan Drug designations 59 Faropenem 59 LymphoStat B 59 CoFactor 59 Fludara 59 oral prodrug 59 Exelbine NDA 59 rFVIIa 59 Roflumilast 59 AzaSite Plus 59 Romidepsin 59 Phase Ib study 59 Velaglucerase Alfa 59 Drug Candidate 59 application sNDA 59 Traficet EN 59 Welchol 59 Onrigin TM 59 Systemic Delivery 59 thalidomide Thalomid 59 REVLIMID R 59 Vidaza azacitidine 59 cell lymphoma CTCL 59 Randomized Phase 59 ATL/TV# 59 ANDA Filing 59 Linjeta TM 59 Announces Tentative Approval 59 approvable letters 59 Tarceva TM 59 MOZOBIL 59 Phase #/#a trial 59 CAMPATH 59 Raptiva ® 59 Ampligen R 59 SinuNase 59 Recombinant Human 59 dasatinib Sprycel ® 59 Tanespimycin 59 Jevtana 59 Receives Orphan Drug Designation 59 Zingo TM 59 Ozarelix 59 Orphan Designation 59 Boxed Warning 59 ENRICH trial 59 ponatinib 59 Dasatinib 59 Full Prescribing Information 59 Lenocta TM 59 Release Capsules 59 dose cohort 59 Investigational Drug 59 ATPace TM 59 Dendreon Provenge 59 Ocrelizumab 59 Tasigna nilotinib 59 Exocrine Pancreatic Insufficiency 59 Initiate Phase 59 Iloperidone 59 Zalbin 59 vilazodone 59 BENLYSTA 59 Zorbtive TM 59 faropenem 59 eprodisate KIACTA TM 59 ZYBRESTAT 59 JAK2 Inhibitor 59 Paragraph IV Certification 59 postoperative ileus POI 59 Genasense ® oblimersen 59 Torisel 59 Aryplase 59 Receives Orphan Drug 59 Package Insert 59 Drug Eluting Stent System 59 Lung Cancer Drug 59 orphan designation 59 IND Investigational New 59 eprodisate Fibrillex TM 59 Marketing Approval PMA 59 chronic idiopathic thrombocytopenic purpura 59 febuxostat 59 DASISION 59 GLP toxicology studies 59 approvable letter 59 Daytrana ® 59 Contrave NDA 59 SPARLON 59 TREANDA 59 TEMODAL 59 Nuvion 59 Genasense 59 BYETTA ® 59 Xcytrin R 59 muraglitazar 59 Corlux 59 Vfend 59 VIVITROL ® 59 Market Approval PMA 59 Keppra ® XR 59 EOquin TM 59 Argatroban 59 Marqibo 59 hypersensitivity allergic reactions 59 LymphoStat B TM 59 IV acetaminophen 59 Lubiprostone 59 PhosLo 59 PDX pralatrexate 59 Metformin GR 59 HCV Protease Inhibitor 59 Q#IR 59 SinuNase ™ 59 Risperidone Oral Solution 59 pixantrone NDA 59 AVASTIN 59 Vilazodone 59 Regeneron Pharma 59 Vaprisol 59 Gout Drug 59 IIa trial 59 cutaneous T 59 European Medicines Evaluation 59 FACTIVE R gemifloxacin 59 Nasdaq Delisting Notification 59 KRN# 59 Improved Survival 59 Successfully Completes Phase 59 LEUKINE 59 Low Dose 59 TAXUS Element Stent System 59 Phase IIB 59 REMOXY NDA 59 NASDAQ Deficiency Notice 59 TLK# 59 Kynapid 59 Boceprevir 59 Oracea TM 59 SmPC 59 Zenpep 59 Going Concern Qualification 59 THALOMID 59 liprotamase 59 PEGINTRON TM 59 Adjunctive Therapy 59 Surgical Mesh 59 sapropterin dihydrochloride 59 Prostate AdenoCarcinoma Treatment 59 OMNARIS Nasal Spray 59 Degarelix 59 sNDA filing 59 Schizophrenia Drug 59 KYNAPID 59 granted Ortec 59 INCB# [001] 59 RAPTIVA 59 NASDAQ Delisting 59 SCHWARZ PHARMA 59 EMBEDA 59 Natalizumab 59 Camvia 59 Orphan Drug status 59 Zensana 59 Protease Inhibitor 59 alemtuzumab MS 59 Advanced Renal Cell 58 Granulocyte Colony Stimulating Factor 58 Known hypersensitivity 58 Etanercept 58 Initiate Phase III 58 Firazyr 58 pralatrexate 58 ULORIC 58 OMNARIS HFA 58 VAPRISOL 58 Somatuline Depot 58 adjuvant GIST 58 Panzem R NCD 58 Ampligen ® 58 NUEDEXTA ™ 58 Glybera R 58 Decitabine 58 Metastatic Colorectal Cancer 58 Polymer Microspheres 58 Fabry Disease 58 PXD# 58 MGd 58 Wellbutrin XL R 58 Azathioprine 58 CLIA waiver 58 DPP4 58 Submits Supplemental 58 Chemophase 58 LUMINATE 58 DexaSite 58 Methylnaltrexone 58 Voluntary Withdrawal 58 maribavir 58 AVADO 58 Inc. Amex SYI 58 PROSTVAC ® 58 hoFH 58 Elagolix 58 PDUFA date 58 Guanilib 58 BEMA TM Fentanyl 58 adalimumab Humira 58 carcinogenicity studies 58 ridaforolimus 58 Androxal TM 58 Lymphoseek ® 58 desvenlafaxine 58 RAV# 58 CLIRS trial 58 enzastaurin 58 Linjeta 58 Drug Application 58 Auxilium Pharma 58 Stavzor 58 IONSYS TM 58 Roche Actemra 58 sNDAs 58 pancreatic insufficiency 58 PROVENGE ® 58 IgG1 monoclonal antibody 58 autologous cellular immunotherapy 58 Evoltra ® 58 Teva Provides Update 58 HCl Injection 58 ACUROX 58 AZILECT ® 58 Diabetic Macular Edema 58 Bosutinib 58 Application MAA 58 ruboxistaurin 58 Nasdaq Deficiency Notice 58 ADVEXIN p# therapy 58 lymphoma CTCL 58 DIFICID ™ 58 Proxinium TM 58 refractory cutaneous T 58 TELINTRA 58 Clolar 58 Application BLA 58 phase IIb trial 58 Investigational Device Exemption 58 Levofloxacin 58 CAELYX 58 BAL# [002] 58 APF# 58 APEX AMI trial 58 REBETOL combination therapy 58 paliperidone palmitate 58 alogliptin 58 Kamada AAT 58 Epilepsy Drug 58 Retisert 58 orBec 58 pegloticase 58 talactoferrin 58 EMBEDA ™ 58 Staff Determination Letter 58 TYZEKA 58 TRISENOX 58 ongoing Phase 1b 58 Plicera 58 Cleviprex TM clevidipine 58 Liprotamase 58 Navelbine ® 58 Combination Treatment 58 MabCampath 58 IMPACT IMmunotherapy 58 Thalomid ® 58 Demonstrates Efficacy 58 brivanib 58 ZEGERID Powder 58 INSPIRE Trial Phase III 58 Potent Antiviral Activity 58 ALN TTR 58 ezogabine 58 methylnaltrexone bromide 58 FDA Approval 58 huN# DM1 58 budesonide foam 58 Issues Complete Response 58 ARIXTRA R 58 YERVOY 58 Amrubicin 58 romidepsin 58 Premarket Notification 58 AZILECT R 58 Pharmacokinetic Study 58 Oral Suspension 58 myelodysplastic myeloproliferative diseases 58 Urocortin 2 58 NASDAQ Hearings Panel 58 PS# [001] 58 mesylate tablets 58 Triolex 58 Topotecan 58 Ciclesonide 58 peginterferon alfa 58 ENDEAVOR IV 58 CAPHOSOL 58 RNAi Therapeutic 58 PROCRIT ® 58 SEROQUEL XR 58 aflibercept 58 Solorel 58 ELADUR 58 V Everolimus Eluting Coronary 58 SANVAR 58 Drug Approvals 58 Pennsaid R 58 Barr ANDA 58 Tesmilifene 58 axitinib 58 Targretin 58 Ranexa R 58 fidaxomicin 58 Xibrom TM 58 Peginterferon alfa 2b 58 Renal Function 58 Immunotherapeutic 58 JAK inhibitor 58 ONGLYZA TM 58 Teriparatide 58 Centralized Procedure 58 panitumumab Vectibix 58 Trodusquemine MSI 58 Fampridine SR NDA 58 Pixantrone 58 proprietary transdermal patch 58 orBec R 58 Combination REOLYSIN R 58 Investigational Oral 58 Osteoporosis Drug 58 ALGRX 58 FDA Anti Infective 58 Gleevec Glivec 58 PNT# 58 Rapaflo 58 Evicel 58 ACTEMRA TM 58 Horizant 58 Virulizin R 58 Voraxaze 58 Hycamtin 58 Dextofisopam 58 Confirmatory Phase 58 Durezol TM 58 Generic Lovenox 58 Fast Track designation 58 SUPPRELIN R LA 58 PNP inhibitor 58 Ozurdex 58 Ceplene 58 prGCD 58 Long Term Efficacy 58 LEP ETU 58 successfully commercialize Iluvien 58 OvaDx 58 PROVIGIL 58 Presents Preclinical Data 58 bicifadine 58 metastatic hormone refractory 58 Pivotal Study 58 Study Evaluating 58 Arthritis Drug 58 naproxen esomeprazole magnesium 58 Initiates Enrollment 58 OraTest 58 preclinical pharmacokinetic 58 Prosaptide 58 terlipressin 58 Androxal ® 58 Prospective Randomized 58 Receives Milestone Payment 58 NUVIGIL 58 SILENOR TM 58 DNAwithPap TM Test 57 Angiox ® 57 FDA Issues Approvable 57 COMFORT II 57 Randomized Phase II 57 miconazole Lauriad ® 57 PROGENSA R 57 tramiprosate ALZHEMED TM 57 Onco TCS 57 Aloxi Injection 57 Chemokine Receptor 57 Plaque Psoriasis 57 HZT 57 Phase IIIb clinical 57 POSIDUR TM 57 PROCRIT R 57 Tamibarotene 57 Genasense ® 57 Nesiritide 57 Temsirolimus 57 trastuzumab DM1 T DM1 57 II Clinical Trial 57 Augment Injectable 57 RSD# 57 FAME Study 57 orally administered inhibitor 57 Antitumor 57 Omacetaxine 57 k premarket 57 PENTASA 57 NASDAQ Delisting Notice 57 CONBRIZA 57 pharmacokinetic PK 57 Troxatyl 57 Uvidem 57 Fungal Infections 57 ENDEAVOR III 57 vidofludimus 57 Presents Positive 57 TELCYTA 57 lomitapide 57 Antiviral Activity 57 rosuvastatin calcium 57 Entecavir 57 TACI Ig 57 Personalized Immunotherapy 57 Dapagliflozin 57 Arimoclomol 57 rilonacept 57 Anti Tumor 57 Silodosin 57 ELND# 57 FIRAZYR 57 Onsolis 57 huC# DM4 57 Present Preclinical Data 57 Indaflex TM 57 diarrhea predominant irritable 57 Acetavance 57 highly purified pasteurized 57 Pulmonary Arterial Hypertension 57 Ceflatonin 57 Vimpat R 57 Achieves Primary Endpoint 57 rhThrombin 57 bazedoxifene 57 adenosine injection 57 Ceflatonin ® 57 troglitazone 57 Evoltra 57 ANDA submission 57 LymphoStat B belimumab 57 Nasdaq Delisting Notice 57 Xcytrin 57 cinacalcet 57 Viramidine 57 therefore therapeutically equivalent 57 IND CTA 57 DATES Comments 57 Cimzia ® certolizumab pegol 57 Extended Release 57 UCB Cimzia 57 GRALISE 57 Hsp# Inhibitor 57 Fludara ® 57 Tygacil 57 Initiates Clinical 57 NexMed Receives 57 Sanvar R 57 GLIADEL R 57 Taxotere ® 57 First Patient Enrolled 57 Saxagliptin 57 Rhucin ® 57 ACUROX ® 57 Resale Registration Statement 57 Prestara TM 57 Paragraph IV certification 57 bifeprunox 57 miconazole Lauriad R 57 acyclovir Lauriad R 57 Employment Inducement Awards 57 Bronchitol 57 ibuprofen Injection 57 APTIMA HPV assay 57 Multiple Ascending Dose 57 Improve Survival 57 PREGNANT Study 57 TNF Blockers 57 Mg Uk 57 Polyphenon ® E 57 virus HCV protease inhibitor 57 Glucophage XR 57 beta 1a 57 treatment naive genotype 57 Nasdaq Notice Regarding 57 Eszopiclone 57 Topline Results 57 ZALBIN 57 Phase III Trials 57 Aurexis 57 non nucleoside inhibitor 57 heterozygous FH 57 BRIM3 57 Exalgo 57 Ixempra 57 DEXILANT 57 ONTAK 57 Zenvia TM 57 Oracea 57 ADVANCE PD 57 Soriatane R 57 Somatuline R Autogel R 57 iloperidone 57 Arranon 57 valdecoxib 57 Navelbine 57 VIAject R 57 Impax ANDA 57 Kinase Inhibitor 57 REMINYL ® 57 AMRIX 57 midstage clinical 57 Loxapine 57 ACAPODENE 57 candesartan cilexetil 57 HCV SPRINT 57 TORISEL TM 57 BioNumerik 57 Frova ® 57 formerly LymphoStat B 57 Ophthalmic Drugs Advisory 57 ITAX 57 Inhalation Solution 57 E1 INT TM 57 Tesamorelin 57 Nebido 57 LAF# 57 Oral Suspension #mg 57 assigned PDUFA 57 Patient Enrolment 57 eritoran 57 XiDay 57 Perflubutane Polymer Microspheres 57 Bevacizumab 57 Gamunex C 57 Desvenlafaxine 57 Dementia Related Psychosis 57 Increlex TM 57 CHMP recommendation 57 PRADAXA 57 CHMP Opinion 57 fluvastatin 57 resubmission 57 ONGLYZA 57 MNTX 57 Safinamide 57 Amyvid 57 prodrug stimulant 57 ecallantide 57 Phase 1a clinical 57 Aurora Kinase 57 Zytiga 57 recurrent glioblastoma multiforme 57 INCB# [002] 57 markets HP Acthar 57 orphan medicinal product 57 Decentralized Procedure 57 Xibrom QD 57 AVOREN 57 #QSB 57 SUTENT ® 57 Mylotarg 57 EndoTAG TM -1 57 REG1 Anticoagulation System 57 SinuNase TM 57 Pentasa 57 Naglazyme 57 Demonstrates Sustained 57 Indomethacin 57 Fidaxomicin 57 Actimmune ® 57 Æterna Zentaris 57 Vicriviroc 57 Orphan Drug Designation 57 Clevudine 57 mertansine 57 EVIZON TM 57 Telatinib 57 refractory APL 57 thymalfasin 57 antibody MT# 57 ganetespib 57 mesylate 57 HCl capsules 57 HuMax EGFr 57 Antiangiogenic 57 TYSABRI natalizumab 57 SURFAXIN 57 METOZOLV ODT 57 Tekturna HCT 57 Noxafil 57 Generic Version Of 57 Promacta 57 Adjuvant Chemotherapy 57 Phase IIb trials 57 Product Characteristics 57 Certican 57 Clinical Trials Update 57 ACOMPLIA R 57 Daytrana TM 57 Besivance 57 Reports Preclinical Data 57 investigational antiplatelet agent 57 testosterone gel LibiGel 57 FENTORA 57 sorafenib tablets 57 PRIALT 57 Focalin XR 57 CANCIDAS 57 systemic immunosuppressive drugs 57 Tracleer R 57 Tavocept 57 Neuromodulation System 57 Receive Milestone Payment 57 AdreView 57 systemic anaplastic large 57 Genasense R oblimersen 57 Restanza 57 First Patient Treated 57 ALN PCS 57 Optimer Pharma 57 Candesartan 57 Pixuvri 57 Aliskiren 57 Sunesis Pharmaceuticals 57 XIAFLEX ™ 56 Xanafide 56 registrational trial 56 Aeolus Pharmaceuticals Announces 56 Entereg TM 56 ketolide antibiotic 56 pioglitazone HCl 56 AQ4N 56 ATL# [001] 56 lesinurad 56 FASLODEX 56 Cloretazine R VNP#M 56 Renvela ® 56 Celebrex celecoxib